- Home
- ABLV vs AEON Comparison
ABLV vs AEON Comparison
Compare ABLV & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ABLV | AEON |
|---|---|---|
| Founded | 2015 | N/A |
| Country | China | United States |
| Employees | 89 | 5 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.4M | 26.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ABLV | AEON |
|---|---|---|
| Price | $0.65 | $0.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.20 |
| AVG Volume (30 Days) | 2.7K | ★ 74.5K |
| Earning Date | 04-23-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.70 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.59 | $0.38 |
| 52 Week High | $1.77 | $1.45 |
Technical Indicators
Market Signals| Indicator | ABLV | AEON |
|---|---|---|
| Relative Strength Index (RSI) | 41.29 | 42.25 |
| Support Level | $0.60 | $0.69 |
| Resistance Level | $0.73 | $1.12 |
| Average True Range (ATR) | 0.04 | 0.12 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 15.46 | 18.13 |
Price Performance
Historical ComparisonAbout ABLV Able View Global Inc.
Able View Global Inc operates as a brand management partner of international beauty and personal care brands in China. It provides full-service solutions covering marketing plan, branding, digital and social marketing, omni-channel sales, customer service, overseas logistics, warehouse, and fulfillment. The firm generates revenue from product sales by distributing and selling cross-border products from various brand owners to Chinese consumers.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.